Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, Randomized, Double-Blind, Placebo- and Active-Controlled, Single and Multiple Ascending Dose Study Evaluating the Comparative Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LFD-200 in Adult Participants Who Are Healthy or Have Moderate to Severe Rheumatoid Arthritis

NCT07207954 is registered in ClinicalTrials.gov with Lifordi Immunotherapeutics, Inc. as lead sponsor.

NCT NCT07207954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07207954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, Randomized, Double-Blind, Placebo- and Active-Controlled, Single and Multiple Ascending Dose Study Evaluating the Comparative Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LFD-200 in Adult Participants Who Are Healthy or Have Moderate to Severe Rheumatoid Arthritis
Lead sponsor
Lifordi Immunotherapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
October 6, 2025
Completion date
July 16, 2027
Enrollment
176 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis